Abstract:Objectives: Conventional cost-effectiveness analysis (CEA) for the value-based pricing of new medicines largely ignores the implications of limited market exclusivity (ie, patent-protection periods plus any exclusivity granted by regulators). This paper explores the implications of this methodological shortcoming, which produces several pricing anomalies with potentially unintended effects on research and development (R&D) incentives. Methods: We illustrate these implications by comparing 4 stylized examples of increasing complexity, from short-term cures for acute conditions to long-term cures for rare, health-catastrophic conditions. Results: (1) Conventional-CEA will project a different result than an adjusted CEA that considers generic or biosimilar entry; (2) free and flexible pricing of long-term treatments (eg, statins for hypercholesterolemia) or repeated-dose cures (eg, insulin for type 1 diabetes) for chronic conditions will likely result in predictable price increases at the end of the exclusivity period that may be perceived as unjustified or unsupported; and (3) one-time administration "cures" (eg, gene therapy for spinal muscular atrophy) have the potential to allocate a large share of the social surplus to the manufacturer over the product lifetime, which may or may not be dynamically efficient per se, but may also inadvertently disadvantage the development of valuable long-term treatments or repeated-dose cures for chronic conditions. Conclusions: We highlight the need for additional research on long-term solutions to these issues that would aim to promote dynamically efficient global R&D. More work is needed on the following: (1) relationships between social surplus allocation and the amount and composition of global R&D, as we may be as likely to be encouraging excessive R&D in some areas as to be undersupplying it in others; and (2) relating the size of the surplus reward to R&D cost and, thus, the return on investment.

From blockbuster to “nichebuster”: how a flawed legislation helped create a new profit model for the drug industry

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks

The next generation of rare disease drug policy: ensuring both innovation and affordability

Paper Promises for Drug Innovation

Pharmaceutical policy and innovation for rare diseases: A narrative review

Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences

Towards ethical drug pricing: the European Orphan Genomic Therapies Fund

Orphan drugs' clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement

Data silos are undermining drug development and failing rare disease patients

Data exclusivity exceptions and compulsory licensing to promote generic medicines in the European Union: A proposal for greater coherence in European pharmaceutical legislation

PHARMACOECONOMICS Affordable orphan drugs: a role for not-for-pro ﬁ t organizations

Drugged Out: How Cognitive Bias Hurts Drug Innovation

Unlocking the full potential of rare disease drug development: exploring the not-for-profit sector's contributions to drug development and access

A Market Shaping Approach for the Biopharmaceutical Industry: Governing Innovation Towards the Public Interest

The Effect of Government Policy on Pharmaceutical Drug Innovation

Why are our medicines so expensive? Spoiler: Not for the reasons you are being told...

Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the "Age of Cures" and Their Implications for Dynamic Efficiency

Little to lose and no other options: Ethical issues in efforts to facilitate expanded access to investigational drugs

Question-based drug development and the value of novel treatments

Upstream solutions for price-gouging on critical generic medicines

Do high drug prices fund pharmaceutical innovation?